Novocure enrolls 1st patient in TTFields, chemo treatment lung cancer phase III trial

Novocure (NSDQ:NVCR) said today it enrolled the 1st patient in the phase 3 pivotal Lunar trial of its Tumor Treating Field technology for treating patients with advanced non-small cell lung cancer who have failed platinum-based therapy. The prospective, randomized 512-patient trial from the St. Helier, N.J.-based company aims to test the safety and efficacy of its TTFields technology in combination with standard of care treatments of immune checkpoint inhibitors or docetaxel. Get the full story at our sister site, Drug Delivery Business News. The post Novocure enrolls 1st patient in TTFields, chemo treatment lung cancer phase III trial appeared first on MassDevice.
Source: Mass Device - Category: Medical Equipment Authors: Tags: Clinical Trials Oncology NovoCure Source Type: news